AAAAAA

   
Results: 1-21 |
Results: 21
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Authors: Bezard, E Brotchie, JM Gross, CE
Citation: E. Bezard et al., Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies, NAT REV NEU, 2(8), 2001, pp. 577-588
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
Authors: Bezard, E Ravenscroft, P Gross, CE Crossman, AR Brotchie, JM
Citation: E. Bezard et al., Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys, NEUROBIOL D, 8(2), 2001, pp. 343-350
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan
Authors: Fox, SH Henry, B Hill, MP Peggs, D Crossman, AR Brotchie, JM
Citation: Sh. Fox et al., Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan, MOVEMENT D, 16(4), 2001, pp. 642-650
Pallidal border cells: An anatomical and electrophysiological study in the1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
Authors: Bezard, E Boraud, T Chalon, S Brotchie, JM Guilloteau, D Gross, CE
Citation: E. Bezard et al., Pallidal border cells: An anatomical and electrophysiological study in the1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey, NEUROSCIENC, 103(1), 2001, pp. 117-123
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease
Authors: Bezard, E Dovero, S Prunier, C Ravenscroft, P Chalon, S Guilloteau, D Crossman, AR Bioulac, B Brotchie, JM Gross, CE
Citation: E. Bezard et al., Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease, J NEUROSC, 21(17), 2001, pp. 6853-6861
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study
Authors: Sieradzan, KA Fox, SH Hill, M Dick, JPR Crossman, AR Brotchie, JM
Citation: Ka. Sieradzan et al., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study, NEUROLOGY, 57(11), 2001, pp. 2108-2111
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease
Authors: Hille, CJ Fox, SH Maneuf, YP Crossman, AR Brotchie, JM
Citation: Cj. Hille et al., Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease, EXP NEUROL, 172(1), 2001, pp. 189-198
mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
Authors: Henry, B Fox, SH Crossman, AR Brotchie, JM
Citation: B. Henry et al., mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease, EXP NEUROL, 171(1), 2001, pp. 139-146
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease
Authors: Silverdale, MA McGuire, S McInnes, A Crossman, AR Brotchie, JM
Citation: Ma. Silverdale et al., Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease, EXP NEUROL, 169(2), 2001, pp. 400-406
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
Authors: Di Marzo, V Hill, MP Bisogno, T Crossman, AR Brotchie, JM
Citation: V. Di Marzo et al., Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease, FASEB J, 14(10), 2000, pp. 1432-1438
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease
Authors: Fox, SH Brotchie, JM
Citation: Sh. Fox et Jm. Brotchie, 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease, MOVEMENT D, 15(6), 2000, pp. 1064-1069
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease
Authors: Brotchie, JM
Citation: Jm. Brotchie, The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease, ANN NEUROL, 47(4), 2000, pp. S105-S114
A common signaling pathway for striatal NMDA and adenosine A(2a) receptors: Implications for the treatment of Parkinson's disease
Authors: Nash, JE Brotchie, JM
Citation: Je. Nash et Jm. Brotchie, A common signaling pathway for striatal NMDA and adenosine A(2a) receptors: Implications for the treatment of Parkinson's disease, J NEUROSC, 20(20), 2000, pp. 7782-7789
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset modelof Parkinson's disease
Authors: Nash, JE Fox, SH Henry, B Hill, MP Peggs, D McGuire, S Maneuf, Y Hille, C Brotchie, JM Crossman, AR
Citation: Je. Nash et al., Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset modelof Parkinson's disease, EXP NEUROL, 165(1), 2000, pp. 136-142
5-HT2C receptor antagonists enhance the behavioural response to dopamine D-1 receptor agonists in the 6-hydroxydopamine-lesioned rat
Authors: Fox, SH Brotchie, JM
Citation: Sh. Fox et Jm. Brotchie, 5-HT2C receptor antagonists enhance the behavioural response to dopamine D-1 receptor agonists in the 6-hydroxydopamine-lesioned rat, EUR J PHARM, 398(1), 2000, pp. 59-64
The alpha(2)-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primatemodel of parkinson's disease
Authors: Henry, B Fox, SH Peggs, D Crossman, AR Brotchie, JM
Citation: B. Henry et al., The alpha(2)-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primatemodel of parkinson's disease, MOVEMENT D, 14(5), 1999, pp. 744-753
Quantitative assessment of dyskinesias in subhuman primates
Authors: Brotchie, JM Fox, SH
Citation: Jm. Brotchie et Sh. Fox, Quantitative assessment of dyskinesias in subhuman primates, MOVEMENT D, 14, 1999, pp. 40-47
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
Authors: Henry, B Crossman, AR Brotchie, JM
Citation: B. Henry et al., Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat, EXP NEUROL, 155(2), 1999, pp. 204-220
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat
Authors: Nash, JE Hill, MP Brotchie, JM
Citation: Je. Nash et al., Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat, EXP NEUROL, 155(1), 1999, pp. 42-48
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat
Authors: Hill, MP Brotchie, JM
Citation: Mp. Hill et Jm. Brotchie, The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat, BR J PHARM, 128(7), 1999, pp. 1577-1585
Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum
Authors: Hill, MP Brotchie, JM
Citation: Mp. Hill et Jm. Brotchie, Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum, BR J PHARM, 127(1), 1999, pp. 275-283
Risultati: 1-21 |